

=>
Uploading 902.str

02/25/98

L8 STRUCTURE UPLOADED

=> s 18

SAMPLE SEARCH INITIATED 08:33:02
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE
100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L9 0 SEA SSS SAM L8

=> s 18 full


FULL SEARCH INITIATED 08:33:09
FULL SCREEN SEARCH COMPLETED - 2 TO ITERATE
100.0% PROCESSED 2 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.03

L10 0 SEA SSS FUL L8

=> d 18

L8 HAS NO ANSWERS

L8 STR



G1 MeO, EtO

Structure attributes must be viewed using STN Express query preparation.

=> fil marpat

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	114.46	315.75

FILE 'MARPAT' ENTERED AT 08:33:24 ON 25 FEB 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1998 American Chemical Society (ACS)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 5700895 23 DEC 1997
DE 19725447 18 DEC 1997
EP 814124 29 DEC 1997
JP 10016376 20 JAN 1998
WO 9749682 31 DEC 1997

NOTICE: MARPAT started covering 1998 patents on 9 February 1998,
with the first entry at 128:61273 for JP10001462 A2, published on
6 January 1998.

*** YOU HAVE NEW MAIL ***

=> s l8

SAMPLE SEARCH INITIATED 08:33:29
SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE
100.0% PROCESSED 7 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.21

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7 TO 299
PROJECTED ANSWERS: 0 TO 0

L11 0 SEA SSS SAM L8

=> s l8 full

FULL SEARCH INITIATED 08:33:57
FULL SCREEN SEARCH COMPLETED - 150 TO ITERATE
96.7% PROCESSED 145 ITERATIONS 1 ANSWERS
100.0% PROCESSED 150 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.35

L12 1 SEA SSS FUL L8


=> d l12 bib ab

L12 ANSWER 1 OF 1 MARPAT COPYRIGHT 1998 ACS
AN 123:82961 MARPAT
TI Preparation of organic nitrate esters having antiinflammatory and/or
analgesic activity
IN Del Soldato, Piero
PA Nicox Ltd., Ire.
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
PI WO 9509831 A1 950413
DS W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP,
KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK,
TJ, TT, UA, US, UZ, VN
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR,
IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 94-EP3182 940923
PRAI GB 93-20599 931006
IT 94-MI916 940510
DT Patent
LA English
OS CASREACT 123:82961
AB The title compds. MCOY[C(A)(B)]nONO2 [A, B = H, (un)branched alkyl;

M = Q1, Q2, 2-(6-methoxy)naphthyl, etc.; n = 1-10], used as analgesics, antiinflammatory agents, and blood platelet aggregation inhibitors, are prepd. Thus, 2-(6-methoxy-2-naphthyl)propionic acid was converted into its Na carboxylate salt with NaOEt, the salt condensed with 1-bromo-4-chlorobutane, and the 4-chlorobutyl 2-(6-methoxy-2-naphthyl)propionate intermediate nitrated by reaction with AgNO₃, producing the 4-nitratobutyl ester, II.

L8

STR




G1 MeO, EtO

Structure attributes must be viewed using STN Express query preparation.





=> d l12 ide can

L12 ANSWER 1 OF 1 MARPAT COPYRIGHT 1998 ACS
AN 123:82961 MARPAT




MSTR 1



G1 = G2 / alkylene (SO)
G2 = (1-10) CH₂
G3 = 9 / 30 / 40 / 53



G4 = 55 / 68 / 81




G5 = O / NH / 89

N—G6
89


G6 = alkyl
MPL: claim 1
NTE: additional ring formation specified

MSTR 2







G1 = 89 / C1 / 91




OH • Na
89



G3 = 9 / 30 / 40 / 53



G4 = 55 / 68 / 81



MPL: claim 15

MSTR 3

G3—G1—G4

G1 = G2 / alkylene (SO)
G2 = (1-10) CH2
G3 = Cl / Br / NH2 / alkylamino
G4 = Cl / Br / I
MPL: claim 15
NTE: additional ring formation specified

MSTR 4

G3—G1—OH

G1 = G2 / alkylene (SO)
G2 = (1-10) CH2
G3 = Cl / Br / NH2 / alkylamino
MPL: claim 16
NTE: additional ring formation specified

123:82961

=> fil beilstein

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	85.24	400.99
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.49	-0.49

FILE 'BEILSTEIN' ENTERED AT 08:36:51 ON 25 FEB 1998
COPYRIGHT (c) 1998 Beilstein Chemiedaten und Software GmbH, Beilstein
Institut fuer Literatur der organischen Chemie

FILE LAST UPDATED: 22 FEB 1998

FILE COVERS 1779 TO 1997.

*** CAS REGISTRY NUMBERS FOR 4,355,879 SUBSTANCES AVAILABLE ***
*** FILE CONTAINS 7,169,346 SUBSTANCES ***

* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *

*** YOU HAVE NEW MAIL ***

=> s 18

SAMPLE SEARCH INITIATED 08:37:02
SCREENING

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE
100.0% PROCESSED 0 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.09

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L13 0 SEA SSS SAM L8

=> s 18 full

FULL SEARCH INITIATED 08:37:29

FULL SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.14

L14 0 SEA SSS FUL L8

=>

Uploading 902570.str


L1 STRUCTURE UPLOADED

=> d 11

02/25/98

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 08:12:08

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 08:12:16

FULL SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> fil marpat

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

113.82

113.97

FILE 'MARPAT' ENTERED AT 08:12:22 ON 25 FEB 1998

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 1998 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 104 ISS 14-VOL 128 ISS 7) (980213/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US, 5700895 23 DEC 1997
DE 19725447 18 DEC 1997
EP 814124 29 DEC 1997
JP 10016376 20 JAN 1998
WO 9749682 31 DEC 1997

NOTICE: MARPAT started covering 1998 patents on 9 February 1998,
with the first entry at 128:61273 for JP10001462 A2, published on
6 January 1998.

=> s 11

SAMPLE SEARCH INITIATED 08:12:27
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE
100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 08:12:34
FULL SCREEN SEARCH COMPLETED - 37 TO ITERATE
100.0% PROCESSED 37 ITERATIONS (1 INCOMPLETE) 3 ANSWERS
SEARCH TIME: 00.00.12

L5 3 SEA SSS FUL L1




=> d 15 1-3 bib ide

L5 ANSWER 1 OF 3 MARPAT COPYRIGHT 1998 ACS
(ALL HITS ARE ITERATION INCOMPLETES)
AN 125:114476 MARPAT
TI Preparation of diol bis-(benzoates or heterocyclylcarboxylates) as
antiinflammatory agents and platelet aggregation inhibitors
IN Del Soldato, Piero; Sannicolo, Francesco; Benincori, Tiziana
PA Laboratori Alchemia S.R.L., Italy
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
PI WO 9615809 A2 960530
DS W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,
GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, TJ
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR,
IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 95-EP4556 951120
PRAI IT 94-MI2362 941122
DT Patent
LA English
AN 125:114476 MARPAT


MSTR 1A

G1—G2—G4—G3—G1
2 4


G1 = R / (SC 85 / 226 / 372 / 436 / 447 / 483 / 568 / 676)














G2 = R / (SC O / C(O))
 G3 = R / (SC O / C(O))
 G4 = O / S / NH / 6 / Cb (SO) / phenylene (SO) /
 Cb<EC (10) C, AN (2-) C, AR (1-), BD (ALL) N, RC (2),
 RS (2) E6 (0) OTHER> (SO) / Hy<EC (1-2) N (0) OTHERQ (4-5)
 C, AN (2-) C (0) N, AR (1-), BD (ALL) N, RC (1), RS (1) E6>
 (SO) / Hy<EC (2) N (3) C (0) OTHERQ, AR (1-), BD (2) D,
 RC (1), RS (1) E5> (SO) / Hy<EC (2) N (7) C (0) OTHERQ,
 AR (1-), BD (6) N (1) D, FA (2) C, RC (2),
 RS (1) E5 (1) E6 (0) OTHER> (SO) / arylene (SO) / 52-2 51-4 /
 73-2 79-4




G5 = cycloalkyl / alkyl
 G14 = O / S
 G19 = 95 / 117 / 137 / 165 / 185 / 208 / 251 / 277 / 328 /
 396 / 409 / 542 / 668

















G20 = H / Et
G21 = H / 223







G22 = 245 / 310 / 359 / 426






G23 = 451 / 464 / 471 / 533 / 554 / 562



G24 = 488 / 502 / 519 / 651




G25 = 587 / 612 / 638








G26 = Me / H
G27 = H / CF3
MPL: claim 1

MSTR 1B ITERATION INCOMPLETE




G2 = R / (SC O / C(O))
G3 = R / (SC O / C(O))
G4 = 8 / C(O) / 12-2 13-4 / Ak (SO) / 15-2 16-4 /
17-2 19-4 / 26-2 28-4 / 29-2 31-4 / 39-2 40-4 / 54-2 58-4 /
G18 / (SC G5 / 696-2 698-4 / 700-2 702-4)







G5 = (2-4) CH2
 G6 = H / cycloalkyl / alkyl
 G7 = alkylene (SO)
 G8 = arylene (SO)
 G9 = (1-3) CH2
 G10 = O / phenylene (SO) / Hy<AR (1-),
 RS (0-) E5 (0-) E6 (0) OTHER> (SO) / 25-17 22-19




G11 = CH2 / C(O)
 G12 = (1-6) CHOH
 G13 = 35 / OH





G15 = S / 59-55 60-57 / 61-55 62-57 / 66














G16 = (1-5) 63-61 65-57



G17 = alkyl (SO) / aryl (SO)
 G18 = (1-4) CHOH
 G19 = 95 / 117 / 137 / 165 / 185 / 208 / 251 / 277 / 328 /
 396 / 409 / 542 / 668








G20 = H / Et
G21 = H / 223.




H₂C—F
223

G27 = H / CF₃
MPL: claim 1

MSTR 1C




G2 = R / (SC O / C(O))
G3 = R / (SC O / C(O))
G4 = 8 / C(O) / 12-2 13-4 / Ak (SO) / 15-2 16-4 /
17-2 19-4 / 26-2 28-4 / 29-2 31-4 / 39-2 40-4 / 54-2 58-4 /
G18 / (SC G5 / 696-2 698-4 / 700-2 702-4)




G5 = (2-4) CH₂
G6 = H / cycloalkyl / alkyl
G7 = alkylene (SO)
G8 = arylene (SO)
G9 = (1-3) CH₂


G10 = O / phenyl (SO) / Hy<AR (1-),
 RS (0-) E5 (0-) E6 (0) OTHER> (SO) / 25-17 19




G11 = CH2 / C(O)
 G12 = (1-6) CHOH
 G13 = 35 / OH







G15 = S / 59-55 60-57 / 61-55 62-57 / 66



G16 = (1-5) 63-61 65-57




G17 = alkyl (SO) / aryl (SO)
 G18 = (1-4) CHOH
 G22 = 245 / 310 / 359 / 426






MPL: claim 1


MSTR 1D




G2 = R / (SC O / C(O))
 G3 = R / (SC O / C(O))
 G4 = 8 / C(O) / 12-2 13-4 / Ak (SO) / 15-2 16-4 /
 17-2 19-4 / 26-2 28-4 / 29-2 31-4 / 39-2 40-4 / 54-2 58-4 /
 G18 / (SC G5 / 696-2 698-4 / 700-2 702-4)




G5 = (2-4) CH2
 G6 = H / cycloalkyl / alkyl
 G7 = alkylene (SO)
 G8 = arylene (SO)
 G9 = (1-3) CH2
 G10 = O / phenylene (SO) / Hy<AR (1-),
 RS (0-) E5 (0-) E6 (0) OTHER> (SO) / 25-17 22-19




G11 = CH2 / C(O)
 G12 = (1-6) CHOH
 G13 = 35 / OH



G15 = S / 59-55 60-57 / 61-55 62-57 / 66



G16 = (1-5) 63-61 65-57




G17 = alkyl (SO) / aryl (SO)


G18 = (1-4) CHOH

MPL: claim 1

MSTR 1E







G1 = 436 / 568




G2 = R / (SC O / C(O))


G3 = R / (SC O / C(O))

G4 = 8 / C(O) / 12-2 13-4 / Ak (SO) / 15-2 16-4 /
17-2 19-4 / 26-2 28-4 / 29-2 31-4 / 39-2 40-4 / 54-2 58-4 /
G18 / (SC G5 / 696-2 698-4 / 700-2 702-4)







G5 = (2-4) CH2
 G6 = H / cycloalkyl / alkyl
 G7 = alkylene (SO)
 G8 = arylene (SO)
 G9 = (1-3) CH2
 G10 = O / phenylene (SO) / Hy<AR (1-),
 RS (0-) E5 (0-) E6 (0) OTHER> (SO) / 25-17 22-19




G11 = CH2 / C(O)
 G12 = (1-6) CHOH
 G13 = 35 / OH






G15 = S / 59-55 60-57 / 61-55 62-57 / 66



G16 = (1-5) 63-61 65-57




G17 = alkyl (SO) / aryl (SO)
 G18 = (1-4) CHOH
 G25 = 587 / 612 / 638




G26 = Me / H
 MPL: claim 1

MSTR 1F









G16 = (1-5) 63-67 5-57



G17 = alkyl (SO) / aryl (SO)


G18 = (1-4) CHOH

G23 = 451 / 464 / 471 / 533 / 554 / 562



MPL: claim 1











MSTR 1G




G2 = R / (SC O / C(O))

G3 = R / (SC O / C(O))


G4 = 8 / C(O) / 12-2 13-4 / Ak (SO) / 15-2 16-4 /
17-2 19-4 / 26-2 28-4 / 29-2 31-4 / 39-2 40-4 / 54-2 58-4 /
G18 / (SC G5 / 696-2 698-4 / 700-2 702-4)




G5 = (2-4) CH2
 G6 = H / cycloalkyl
 G7 = alkylene (SO)
 G8 = arylene (SO)
 G9 = (1-3) CH2
 G10 = O / phenylene (SO) / Hy<AR (1-),
 RS (0-) E5 (0-) E6 (0) OTHER> (SO) / 25-17 22-19




G11 = CH2 / C(O)
 G12 = (1-6) CHOH
 G13 = 35 / OH







G15 = S / 59-55 60-57 / 61-55 62-57 / 66



G16 = (1-5) 63-61 65-57




G17 = alkyl (SO) / aryl (SO)
 G18 = (1-4) CHOH
 G24 = 488 / 502 / 519 / 651






MPL: claim 1


MSTR 1H




G2 = R / (SC O / C(O))
 G3 = R / (SC O / C(O))
 G4 = 8 / C(O) / 12-2 13-4 / Ak (SO) / 15-2 16-4 /
 17-2 19-4 / 26-2 28-4 / 29-2 31-4 / 39-2 40-4 / 54-2 58-4 /
 G18 / (SC G5 / 696-2 698-4 / 700-2 702-4)




G5 = (2-4) CH2
 G6 = H / cycloalkyl / alkyl
 G7 = alkylene (SO)
 G8 = arylene (SO)
 G9 = (1-3) CH2
 G10 = O / phenylene (SO) / Hy<AR (1-),
 RS (0-) E5 (0-) E6 (0) OTHER> (SO) / 25-17 22-19




G11 = CH2 / C(O)
 G12 = (1-6) CHOH
 G13 = 35 / OH



G15 = S / 59-55 60-57 / 61-55 62-57 / 66



G16 = (1-5) 63-61 65-57



G17 = alkyl (SO) / aryl (SO)

G18 = (1-4) CHOH

MPL: claim 1

L5 ANSWER 2 OF 3 MARPAT COPYRIGHT 1998 ACS

AN 124:201789 MARPAT

TI Preparation of aryl nitrate ester compounds having antiinflammatory
ans well as analgesic and antithrombotic activities

~~IN Del Soldato, Piero; Sannicolo, Francesco~~

PA Nicox Ltd., Ire.

SO PCT Int. Appl., 87 pp.

CODEN: PIXXD2

PI WO 9530641 A1 951116

DS W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP,
KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SI,
SK, TJ, TT, UA, US, UZ, VN

RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR,
IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG

AI WO 95-EP1233 950404

PRAI IT 94-MI916 940510


IT 94-MI1731 940809

DT Patent




LA English

AN 124:201789 MARPAT










MSTR 1A





G1 = 4 / 126 / 149 / 326 / 424 / 480 / 525 / 589 / 602 /
625 / 635 / 660 / 678 / 712 / 717 / 735



Ph-p-C₆H₄C(O)·CH₂-G15-^{G2}₃₂₆ G29-G27-C(O)-^{G2}₄₂₄












G2 = O / 7

N—G3
 7


G3 = H / alkyl<(1-10)>

G4 = Ph (SR (1-2) G5) / 18 / 26 / 36 / 57 / 64 / 80 / 103



G5 = (1) G6 / (-1) G8




G6 = 9 / Hy<EC (0-) N (0-) O (0-) S (0) OTHERQ, RC (1),
 RS (1) M5 (1) X6>



G7 = Me / Et / alkyl<(3-5)>


G8 = OH / X / alkyl<(1-4)> / alkoxy<(1-4)> /
 perfluoroalkyl<(1-4)> / CF₃ / NO₂ / NH₂ / alkylamino<(1-4)> /
 dialkylamino<(1-4)>

G9 = o-C₆H₄ (SO (1-2) G10) / 42-35 43-5 / 52-35 53-5 /
 778-35 779-5



G10 = (-1) G6 / (-1) G8

G11 = 134 / 137




G12 = H / alkyl<(1-3)>

G13 = H / alkyl<(1-6)> / alkoxy<(1-6)> / Cl / F / Br














G14 = (2-) H / alkyl<(1-6)> / alkoxy<(1-6)> / Cl / F / Br









G15 = 150 / 153 / CHMe



G16 = H / alkyl<(1-12)> (SO)

G17 = 163 / 173 / 187 / 201 / 215 / 237 / 249 / 263 /
264 / 275 / 285 / 294 / 303 / 306 / 315 / 330 / 353 / 385 /
395 / 407 / 372 / 413







- G18 = H / alkyl<(1-6)> (SO alkoxy carbonyl<(1-6)>) /
alkyl<(1-6)> (SR CO2H) / alkyl carbonyl<(1-6)> (SO (1-) X) /
CH2Ph (SO (1-) X) / CPh (SO (1-) X)
- G19 = H / (-1) G20 / (1) G22
- G20 = X / OH / CN / alkyl<(1-6)> (SO G21) /
alkoxy<(1-6)> / COMe / OCH2Ph / alkylthio<(1-6)> /
perfluoroalkyl<(1-3)> / NO2 / NH2 / SO2NH2 /
dialkylaminosulfonyl<(1-6)> / alkylsulfonyl<(1-3)> (SR (2) F)
- G21 = OH / CO2H
- G22 = X / CN / alkyl<(1-6)> (SO (1-) OH) / alkoxy<(1-6)> /
COMe / NHCOMe / OCH2Ph / alkylthio<(1-6)> /
perfluoroalkyl<(1-3)> / OH / alkyl<(1-6)> (SR CO2H) / NO2 /
NH2 / alkylamino<(1-6)> / dialkylamino<(1-6)> / SO2NH2 /
dialkylaminosulfonyl<(1-6)> / alkylsulfonyl<(1-3)> (SR (2) F)
- G23 = H / alkylthio<(1-4)>
- G24 = H / OH
- G25 = Ph (SO (1-) G26) / heteroaryl / thienyl /
furyl (SO OH) / pyridyl
- G26 = OH / X / alkyl carbonyl<(1-6)> / alkoxy<(1-6)> /
alkyl<(1-6)> / cyclopentyl / cyclohexyl / cycloheptyl
- G27 = 425 / C=CH2

HC—G28
425


- G28 = H / alkyl<(1-6)> (SO (2) F) / Me
- G29 = 435 / 445 / 446




p-C6H4G33
446

- G30 = alkyl<(1-6)> / cycloalkyl<(3-7)> / 448 /
alkyl<(1-3)> (SR (3) F) / CH=CH2 / ethynyl / X /
alkoxy<(1-6)> / alkoxy<(1-7)> (SR (2) F) / 452 / CN / 453 /




Ph (SO alkyl<(1-8)>) / OMe




G31 = alkoxy<(1-7)> / alkylthio<(1-7)>
G33 = alkyl<(2-5)> / alkoxy<(2-3)> / 456 / OPh / SPh /
cycloalkyl<(5-7)> (SO (1) alkyl<(1-2)>) / Bu-i




G34 = 737-1 738-3 / 481-1 503-3 / 739-1 742-3 /
743-1 746-3 / 747-1 753-3 / 760-1 763-3



G35 = H / alkyl<(1-4)>
G36 = **phenylene**
G37 = H / alkyl<(1-4)> / alkoxy<(1-4)> / Cl / F / Br
G38 = H / Cl
G39 = phenylene
G40 = **alkylene<(1-20)>** / cycloalkylene<(5-7)> (SO)
G41 = (2-3) CH₂
G42 = phenylene
G43 = phenylene (SO (1) CO₂H)
G44 = (0-5) 754-750 757-3




G45 = (1-) H / Me
G46 = (0-5) 766-762 768-3




G47 = CO₂H (SO)
DER: or salts
MPL: claim 1

NTE: additional ring formation is allowed
 NTE: substitution restricted



MSTR 1B




G1 = 481 / 560 / 574




G4 = 737-1 738-3 / 4-1 6-3 / 739-1 742-3 / 743-1 746-3 /
 747-1 753-3 / 760-1 763-3




G5 = phenylene
 G34 = 503 / 547



G40 = alkylene<(1-20)> / cycloalkylene<(5-7)> (SO)
 G41 = (2-3) CH2
 G42 = phenylene
 G43 = phenylene (SO (1) CO2H)
 G44 = (0-5) 754-750 757-3




G45 = (1-) H / Me
 G46 = (0-5) 766-762 768-3







DER: or salts
MPL: claim 1
NTE: additional ring formation is allowed
NTE: substitution is restricted

L5 ANSWER 3 OF 3 MARPAT COPYRIGHT 1998 ACS
AN 123:82961 MARPAT
TI Preparation of organic nitrate esters having antiinflammatory and/or analgesic activity
IN ~~Del Soldato, Piero~~
PA Nicox Ltd., Ire.
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
PI WO 9509831 A1 950413
DS W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 94-EP3182 940923
PRAI GB 93-20599 931006
IT 94-MI916 940510
DT Patent
LA English
OS CASREACT 123:82961
AN 123:82961 MARPAT




MSTR 1




G1 = G2 / alkylene (SO)
G2 = (1-10) CH₂
G3 = 9 / 30 / 40 / 53



G4 = 55 / 68 / 81



G5 = O / NH / 89




G6 = alkyl



MPL: claim 1

NTE: additional ring formation specified





MSTR 2






G1 = 89 / Cl / 91



G3 = 9 / 30 / 40 / 53



G4 = 55 / 68 / 81



MPL: claim 15

MSTR 3

G3—G1—G4

G1 = G2 / alkylene (SO)
G2 = (1-10) CH2
G3 = Cl / Br / NH2 / alkylamino
G4 = Cl / Br / I
MPL: claim 15
NTE: additional ring formation specified

MSTR 4

G3—G1—OH

G1 = G2 / alkylene (SO)
G2 = (1-10) CH2
G3 = Cl / Br / NH2 / alkylamino
MPL: claim 16
NTE: additional ring formation specified

=> fil beilstein

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	87.32	201.29

FILE 'BEILSTEIN' ENTERED AT 08:14:01 ON 25 FEB 1998
COPYRIGHT (c) 1998 Beilstein Chemiedaten und Software GmbH, Beilstein
Institut fuer Literatur der organischen Chemie

FILE LAST UPDATED: 22 FEB 1998

FILE COVERS 1779 TO 1997.

*** CAS REGISTRY NUMBERS FOR 4,355,879 SUBSTANCES AVAILABLE ***
*** FILE CONTAINS 7,169,346 SUBSTANCES ***

* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *

*** YOU HAVE NEW MAIL ***

=> s 11

SAMPLE SEARCH INITIATED 08:14:07
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE
100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.08

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS:
PROJECTED ANSWERS:

0 TO 0
0 TO 0

L6 0 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 08:14:24
SCREENING

FULL SCREEN SEARCH COMPLETED - 0 TO ITERATE
100.0% PROCESSED 0 ITERATIONS
SEARCH TIME: 00.00.21

0 ANSWERS

L7 0 SEA SSS FUL L1